L’Oreal announced that it has completed the acquisition of Lactobio, a leading probiotic and microbiome research company based in Copenhagen. L’Oreal said that the strategic acquisition “builds on 20 years of advanced research by L’Oreal into the microbiome scientific territory, deepening its knowledge of the microorganisms that live on the skin’s surface and reinforcing the Groupe’s leadership in this field. The acquisition also opens up new scientific opportunities, including leveraging Lactobio’s microbiome expertise and significant IP portfolio to develop safe and effective new cosmetic solutions using live bacteria.” Terms of the deal were not disclosed.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LRLCY:
- L’Oreal price target raised to EUR 420 from EUR 400 at JPMorgan
- L’Oreal upgraded to Overweight from Equal Weight at Morgan Stanley
- L’Oreal price target lowered to EUR 389 from EUR 392 at Berenberg
- L’Oreal price target raised to EUR 431 from EUR 423 at Barclays
- L’Oreal reports Q3 like-for-like sales up 11.1%
